Targeting the 90 kDa heat shock protein improves photodynamic therapy

Cancer Letters

Volumn 289, Issue 2, 2010, Pages 188-194

  Ferrario, Angela ^a   Gomer, Charles J ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

17 AAG; Apoptosis; Geldanamycin; Hsp 90; Photodynamic therapy (PDT)

Indexed keywords

GELATINASE A; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN KINASE B; SURVIVIN; TANESPIMYCIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CELL SURVIVAL; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; TREATMENT RESPONSE;

ANIMALS; APOPTOSIS; BENZOQUINONES; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C3H; PHOTOCHEMOTHERAPY; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTORS;

MUS;

EID: 76849090809     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.08.015     Document Type: Article

References (36)

1. Dougherty T.J., Gomer C.J., Henderson B.W., Jori G., Kessel D., Korbelik M., Moan J., and Peng Q. Photodynamic therapy. J. Natl. Cancer Inst. 90 (1998) 889-905
2. Oleinick N.L., and Evans H.H. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat. Res. 150 (1998) s146-s156
3. Dolmans D.E., Fukamura D., and Jain R.K. Photodynamic therapy of cancer. Nat. Rev. Cancer 3 (2003) 380-387
4. Moor A.C. Signaling pathways in cell death and survival after photodynamic therapy. J. Photochem. Photobiol. B-Biol. 57 (2000) 1-13
5. Kessel D., and Reiners J.J. Apoptosis and autophagy after mitochondrial or endoplasmic reticulum photodamage. Photochem. Photobiol. 83 (2007) 1024-1028
6. Gomer C.J., Ferrario A., Luna M., Rucker N., and Wong S. Photodynamic therapy: combined modality approaches targeting the tumor microenvironment. Lasers Surg. Med. 38 (2006) 516-521
7. Gollnick S.O., Evans S.S., Baumann H., Owczarczak B., Maier P., Vaughan L., Wang W.C., Unger E., and Henderson B.W. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br. J. Cancer 88 (2002) 1772-1779
8. Ferrario A., von Tiehl K.F., Rucker N., Schwarz M.A., Gill P.S., and Gomer C.J. Anti-angiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 60 (2000) 4066-4069
9. Ferrario A., and Gomer C.J. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. J. Environ. Pathol. Oncol. 25 (2006) 251-259
10. Ferrario A., Chantrain C.F., von Tiehl K., Buckley S., Rucker N., Shalinsky D.R., Shimada H., DeClerck Y.A., and Gomer C.J. The matrix metalloproteinase inhibitor Prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res. 64 (2004) 2328-2332
11. Ferrario A., von Tiehl K.F., Wong S., Luna M., and Gomer C.J. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res. 62 (2002) 3956-3961
12. Ferrario A., Fisher A., Rucker N., and Gomer C.J. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res. 65 (2005) 9473-9478
13. Bozkulak O., Wong S., Luna M., Ferrario A., Rucker N., Gulsoy M., and Gomer C.J. Multiple components of photodynamic therapy can phosphorylate Akt. Photochem. Photobiol. 83 (2007) 1029-1033
14. Ferrario A., Rucker N., Wong S., Luna M., and Gomer C.J. Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response. Cancer Res. 67 (2007) 4989-4995
15. Bagatell R., and Whitesell L. Altered hsp90 function in cancer: a unique therapeutic opportunity. Mol. Cancer Ther. 3 (2004) 1021-1030
16. Chaudhury S., Welch T.R., and Blagg B.S.J. Hsp90 as a target for drug development. Chem. Med. Chem. 1 (2006) 1331-1340
17. Tsutsumi S., and Neckers L. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci. 98 (2007) 1536-1539
18. Kregel K.C. Heat shock proteins: modifying factors in physiological stress responses and acquired thermotolerance. J. Appl. Physiol. 92 (2002) 2177-2186
19. Neckers L., and Ivy S.P. Heat-shock protein 90. Curr. Opin. Oncol. 15 (2003) 419-422
20. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin. Cancer Res. 15 (2009) 9-14
21. Powers M.V., and Workman P. Targeting of multiple signaling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocrine-Related Cancers 13 (2006) s125-s135
22. Zhang H.Y., Chung D., Yang Y.-C., Neely L., Tsurumoto S., Fan J., Zhang L., Biamonte M., Brekken J., Lundgren K., and Burrows F.J. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol. Cancer Ther. 5 (2006) 1256-1264
23. Hopper C. Photodynamic therapy: a clinical reality in the treatment of cancer. Lancet Oncol. 1 (2000) 212-219
24. Dougherty T.J. An update on photodynamic therapy applications. J. Clin. Laser Med. Surg. 20 (2002) 3-7
25. Tong Z., Singh G., Valerie K., and Rainbow A.J. Activation of the stress-activated JNK and p38 MAP kinases in human cells by Photofrin-mediated photodynamic therapy. J. Photochem. Photobiol. B. 15 (2003) 77-85
26. Verma S., Watt G.M., Mai Z., and Hasan T. Strategies for enhancing photodynamic therapy effects. Photochem. Photobiol. 83 (2007) 996-1005
27. Sonveaux P., Bronet A., Havanx X., Gregorire V., Dosy C., Balligand J.-L., and Feron O. Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway. Cancer Res. 63 (2003) 1012-1019
28. Fohy B.N., Schlieman M.G., Virudachalam S., and Bold R.J. Inhibition of AKT abrogates chemotherapy induced NFkB survival mechanisms: implications for therapy in pancreatic cancer. J. Am. Coll. Surg. 198 (2004) 591-599
29. Workman P., Burrows F., Neckers L., and Rosen N. Drugging the cancer chaperone Hsp90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. NY Acad. Sci. 1113 (2007) 202-216
30. Ramanathan R.K., Egorin M.J., Eiseman J., Ramalingam S., Friedland D., Agarwala S.S., Ivy S.P., Potter D., Chatta G., Zuhowski E.G., Stoller R.G., Naret C., Guo J., and Belani C.P. Phase 1 and pharmacodynamics study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin. Cancer Res. 13 (2007) 1769-1774
31. Heath E.I., Hillman D.W., Vaishampayan U., Sheng S., Sarkar F., Harper F., Gaskins M., Pitot H.C., Tan W., Ivy S.P., Pili R., Carducci M.A., Erlichman C., and Lui G. A phase II trial 17-allylamino-17-demthoxygeldanamycin in patients with hormone refractory metastatic prostate cancer. Clin. Cancer Res. 14 (2008) 7940-7946
32. Nonaka M., Ikeda H., and Inokuchi T. Inhibitory effect of heat shock protein 70 on apoptosis induced by photodynamic therapy in vitro. Photochem. Photobiol. 79 (2004) 94-98
33. Rucker N., Ferrario A., and Gomer C.J. Constitutive over-expression of HSP-70 in thermal resistant tumor cells does not alter sensitivity to porphyrin, chlorin or purpurin mediated PDT. J. Porphyr. Phthalocya. 5 (2001) 143-146
34. Gomer C.J., Ferrario A., Rucker N., Wong S., and Lee A. Glucose regulated protein (GRP-78) induction and cellular resistance to oxidative stress mediated by porphyrin photosensitization. Cancer Res. 51 (1991) 6574-6579
35. Gyurkocza B., Plescia J., Raskett C.M., Garlick D.S., Lowry P.A., Carter B.Z., Andreeff M., Meli M., Colombo G., and Altieri D.C. Antileukemic activity of shepherdin and molecular diversity of Hsp-90 inhibitors. J. Natl. Cancer Inst. 98 (2006) 1068-1077
36. Banerji U., Sain N., Sharp S.Y., Valenti M., Asad Y., Ruddle R., Raynaud F., Walton M., Eccles S.A., Judson I., Jackman A.L., and Workman P. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother. Pharmacol. 62 (2008) 769-778